- Home
- UHG vs ENTA Comparison
UHG vs ENTA Comparison
Compare UHG & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- ENTA
- Stock Information
- Founded
- UHG 2004
- ENTA 1995
- Country
- UHG United States
- ENTA United States
- Employees
- UHG N/A
- ENTA N/A
- Industry
- UHG Homebuilding
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- UHG Consumer Discretionary
- ENTA Health Care
- Exchange
- UHG Nasdaq
- ENTA Nasdaq
- Market Cap
- UHG 158.8M
- ENTA 164.6M
- IPO Year
- UHG N/A
- ENTA 2013
- Fundamental
- Price
- UHG $3.14
- ENTA $6.57
- Analyst Decision
- UHG
- ENTA Buy
- Analyst Count
- UHG 0
- ENTA 4
- Target Price
- UHG N/A
- ENTA $18.00
- AVG Volume (30 Days)
- UHG 231.7K
- ENTA 157.6K
- Earning Date
- UHG 08-07-2025
- ENTA 08-04-2025
- Dividend Yield
- UHG N/A
- ENTA N/A
- EPS Growth
- UHG N/A
- ENTA N/A
- EPS
- UHG 0.76
- ENTA N/A
- Revenue
- UHG $449,877,017.00
- ENTA $64,462,999.00
- Revenue This Year
- UHG N/A
- ENTA N/A
- Revenue Next Year
- UHG N/A
- ENTA $0.48
- P/E Ratio
- UHG $4.06
- ENTA N/A
- Revenue Growth
- UHG 5.24
- ENTA N/A
- 52 Week Low
- UHG $1.60
- ENTA $4.09
- 52 Week High
- UHG $6.93
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- UHG 49.50
- ENTA 45.50
- Support Level
- UHG $2.71
- ENTA $6.95
- Resistance Level
- UHG $2.95
- ENTA $8.23
- Average True Range (ATR)
- UHG 0.33
- ENTA 0.40
- MACD
- UHG -0.07
- ENTA -0.10
- Stochastic Oscillator
- UHG 28.24
- ENTA 7.42
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.